Table 2. Medications taken by disease type.
| Class of medication | Medication name | RRMS | PPMS | SPMS | PRMS | BMS | Unknown MS type | Missing* | Total |
| First generation DMDS | Glatiramer acetate | 384 (78.7) | 10 (2.0) | 6 (1.2) | 6 (1.2) | 8 (1.6) | 52 (10.7) | 22 (4.5) | 488 (100) |
| Interferons | 338 (78.1) | 7 (1.6) | 5 (1.2) | 5 (1.2) | 8 (1.8) | 44 (10.2) | 26 (6.0) | 433 (100) | |
| Second generation DMDs | Natalizumab | 103 (78.0) | 6 (4.5) | 7 (5.3) | 7 (5.3) | 0 (0) | 8 (6.0) | 1 (0.8) | 132 (100) |
| Alemtuzumab | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (0.0) | 2 (100) | |
| Daclizumab | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 1 (100) | |
| Rituximab | 2 (100.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | |
| Fingolimod | 67 (71.3) | 6 (6.4) | 1 (1.1) | 1 (1.1) | 1 (1.1) | 8 (8.5) | 10 (10.6) | 94 (100) | |
| Dimethyl fumarate | 11 (50.0) | 1 (4.5) | 1 (4.5) | 1 (4.5) | 1 (4.5) | 3 (27.2) | 4 (18.2) | 22 (100) | |
| Teriflunomide | 3 (75.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (25.0) | 0 (0) | 4 (100) | |
| Cladribine | 1 (50.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (50.0) | 2 (100) | |
| Laquinimod | 3 (100.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (100) | |
| General immunosuppressants | Azathioprine | 1 (14.3) | 1 (14.3) | 0 (0) | 0 (0) | 0 (0) | 1 (14.3) | 4 (57.1) | 7 (100) |
| Cyclophosphamide | 0 (0) | 1 (100.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | |
| Methotrexate | 3 (60.0) | 1 (20.0) | 0 (0) | 1 (20.0) | 0 (0) | 0 (0) | 0 (0) | 5 (100) | |
| Mitoxantrone | 1 (25.0) | 1 (25.0) | 0 (0) | 0 (0) | 0 (0) | 1 (25.0) | 1 (25.0) | 4 (100) | |
| Mycophenolate | 1 (20.0) | 2 (40.0) | 0 (0) | 1 (20.0) | 1 (20.0) | 0 (0) | 0 (0) | 5 (100) | |
| Steroids | Adrenocorticotropic hormone (ACTH) | 3 (33.3) | 1 (1.1) | 1 (1.1) | 0 (0) | 0 (0) | 3 (33.3) | 1 (1.1) | 9 (100) |
| Prednisolone | 94 (65.3) | 12 (8.3) | 3 (2.1) | 3 (2.1 | 3 (2.1) | 19 (13.2) | 10 (6.9) | 144 (100) | |
| Others | Immunoglobulins | 2 (40.0) | 2 (40.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (20.0) | 5 (100) |
| Plasmapheresis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (100) | |
| LDN | 72 (44.2) | 23 (14.1) | 3 (1.8) | 3 (1.8) | 1 (0.6) | 26 (3.7) | 35 (21.5) | 163 (100) | |
| Minocycline | 11 (68.8) | 1 (6.3) | 0 (0) | 0 (0) | 0 (0) | 4 (25.0) | 0 (0) | 16 (100) | |
| Baclofen | 91 (37.6) | 38 (15.7) | 12 (5.0) | 12 (5.0) | 2 (0.8) | 25 (10.3) | 62 (0.1) | 242 (100) | |
| Fampridine | 30 (37.5) | 11 (13.8) | 5 (6.3) | 5 (6.3) | 0 (0) | 14 (17.5) | 15 (18.8) | 80 (100) |
DMD: disease-modifying drug; RRMS: relapsing-remitting MS; PPMS: primary progressive MS; SPMS: secondary progressive MS; PRMS: progressive relapsing MS; BMS: benign MS; LDN: low-dose naltrexone.
*
Data for type of MS not provided by respondent.